Korro Bio, Inc.

NASDAQ•KRRO

執行長: Mr. Nessan Bermingham Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

聯絡資訊

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

市值

$128.59M

本益比 (TTM)

-1.1

股息率

52周最高

$55.89

52周最低

$5.20

52周範圍

17%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基於 8 年期基本面

疲弱 • 2.2 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2018-2025

財務儀表板

Q4 2025 數據

營業收入

$1.29M+0.00%

近4季度走勢

每股收益

-$5.33+0.00%

近4季度走勢

自由現金流

-$17.79M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Collaboration Revenue Increased Collaboration revenue reached $6.4M USD in 2025, up $4.1M USD from $2.3M USD in 2024, driven by Novo Nordisk agreement.

KRRO-121 Advancement Progressing Lead candidate KRRO-121 targets hyperammonemia with regulatory filing anticipated in the second half of 2026 for first-in-human trial.

AATD Candidate Nomination Nearing Next-generation AATD program expects development candidate nomination in the second quarter of 2026 following pivot to GalNAc delivery.

Cash Runway Extended Cash runway extends into the second half of 2028 supporting key milestones after recent financing activities and restructuring efforts.

關注風險

Continued Operating Losses Expected Net loss widened to $(117.3M) USD in 2025 from $(83.6M) USD in 2024; expects increasing expenses and negative cash flow indefinitely.

Significant Asset Impairment Recognized $30.9M USD non-cash impairment charge in Q4 2025 related to operating lease and fixed assets following program termination.

Pipeline Concentration Risk High Business heavily reliant on KRRO-121 success; only nominated candidate after terminating KRRO-110 program due to insufficient functional protein levels.

Novel Technology Unproven RNA editing technology is new with limited clinical validation; preclinical success does not guarantee positive results in human trials.

未來展望

Advance KRRO-121 Clinical Trial Anticipate regulatory filing for KRRO-121 in H2 2026 to commence first-in-human trial for hyperammonemia treatment indications.

Optimize OPERA Platform Further Continue enhancing OPERA platform using computational models and new data to expedite design and optimization of future lead candidates.

Advance ALS and Longevity Programs Continue advancing ALS program targeting TDP-43 aggregation and longevity program targeting AMPKγ1 activation through preclinical studies.

Seek Strategic Partnerships Plan to actively seek innovative collaborations and strategic alliances to maximize OPERA platform potential across rare and prevalent diseases.

同行對比

營業收入 (TTM)

AMRN

$183.87M

-19.6%

ADCT

$81.36M

+14.9%

AUTL

$75.35M

+644.6%

毛利率 (最新季度)

AMRN

119.2%

+7.3pp

ALT

100.0%

-299200.0pp

ADCT

84.5%

-2.7pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$759.43M	-4.8	-101.3%	9.4%
ADCT	$555.18M	-4.6	66.2%	135.9%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-20.3%

增長承壓

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月5日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料